ArticleOncology letters2026
Vanishing liver metastases in pancreatic cancer: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic pancreatic cancer carries a poor prognosis, with palliative chemotherapy offering limited survival benefit and conversion to resectability considered rare. The present study reports the case of a 60-year-old woman with pancreatic adenocarcinoma and extensive liver metastases treated with palliative FOLFIRINOX, achieving complete radiological disappearance of hepatic disease and sustained control of the primary tumour. After a treatment pause and subsequent reinitiation of chemotherapy for local progression, the liver metastases remained absent. At 32 months post-diagnosis, the patient underwent pancreatic resection with negative margins and remains alive and free from hepatic recurrence 84 months from diagnosis. This case highlights that select patients may achieve long-term survival through individualized, multimodal treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.